Tariquidar (dihydrochloride)
Product Specifications
UNSPSC Description
Tariquidar dihydrochloride (XR9576 dihydrochloride) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (Kd=5.1 nM)[1].
Target Antigen
P-glycoprotein
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tariquidar-dihydrochloride.html
Solubility
10 mM in DMSO
Smiles
[H]Cl.[H]Cl.O=C(C1=CC2=CC=CC=C2N=C1)NC3=CC(OC)=C(OC)C=C3C(NC4=CC=C(CCN5CC6=C(C=C(OC)C(OC)=C6)CC5)C=C4)=O
Molecular Weight
719.65
References & Citations
[1]Martin C, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol, 1999, 128(2), 403-411.|[2]Mistry P, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res, 2001, 61(2), 749-758.J Control Release. 2021 Dec 28;342:44-52.|Antimicrob Agents Chemother. 2015 Nov 30;60(2):946-54. |Antioxidants (Basel). 2021 Jun 11;10(6):949.|Antioxidants (Basel). 2024 Sep 1.|Antiviral Res. 2021 Jun 28;105124.|Cell Death Discov. 2021 Aug 5;7(1):204.|Cell. 2023 Dec 7;186(25):5500-5516.e21.|Commun Chem. 2024 Jul 13;7(1):158.|Crit Rev Anal Chem. 2021 Mar 10;1-15.|Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):599-606.|Eur J Med Chem. 2017 Feb 15;127:586-598. |Eur J Med Chem. 2018 Mar 10;147:7-20. |Eur J Pharm Sci. 2019 Jan 15;127:319-329.|Eur J Pharmacol. 2024 Feb 21:176431.|Hepatol Commun. 2024 May 2;8(5):e0437.|Int J Mol Sci. 2022, 23(23), 14948.|Int J Mol Sci. 2023 Mar 10.|J Biomed Nanotechnol. 2018 Oct 1;14(10):1705-1718.|J Cereb Blood Flow Metab. 2016 Aug;36(8):1412-23. |J Cereb Blood Flow Metab. 2021 Jul;41(7):1634-1646.|J Control Release. 2022 Jul 8;349:109-117.|J Drug Deliv Sci Technol. May 2022, 103323.|J Nanopart Res. (2018) 20:176.|J Nat Prod. 2022 Nov 22.|Langmuir. 2015 May 12;31(18):5115-22. |Mar Drugs. 2022, 20(10), 597.|Mar Drugs. 2022, 20(12), 738|Mar Drugs. 2023 Mar 14.|Mar Drugs. 2023, 21(1), 54.|Mar Drugs. 2024 Aug 30.|Mol Pharm. 2019 Mar 4;16(3):1282-1293. |Mol Pharm. 2021 Jan 4;18(1):416-428.|Pharm Res. 2017 Jan;34(1):148-160.|Pharmaceuticals. 2023 Feb 24; Feb 16(3), 349.|Pharmaceutics. 2021 Feb 26;13(3):306.|PLoS One. 2017 Sep 15;12(9):e0183662. |Research Square Preprint. 2021 Mar.|Research Square Preprint. 2024 Feb 6.|Research Square Print. 2022 Jul.|RSC Adv. 2016,6, 69083-69093.|Sci Bull. 2016 Apr;61(7):552-560.|Sci Rep. 2017 Dec 22;7(1):18069.|Sci Rep. 2022 Aug 9;12(1):13570.|Small. 2020 Nov;16(44):e2004172.|Xenobiotica. 2020 Mar;50(3):354-362. |J Cereb Blood Flow Metab. 2020 Jan;40(1):150-162.|Mol Imaging Biol. 2019 Apr;21(2):257-268. |Mol Pharm. 2020 Sep 8;17(9):3477-3486.|Nucl Med Biol. 2018 May;60:29-36. |RWTH Aachen University. 2021 Oct.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-110377/Tariquidar-dihydrochloride-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-110377/
Clinical Information
Phase 3
CAS Number
1992047-62-7
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
E12C2022-01 48 Well
Chicken Carbamoyl phosphate synthase [ammonia], mitochondrial (CPS1) ELISA Kit
Ask
View Details